Since the claim is that “DD3 is one of the most prostate cancer-specific genes yet described” [7], testing PCA3 level in variants clinical specimens including blood, urine, ejaculate, and other body fluid was sequentially proposed and clinically conducted [14–16]. The gene discussed is PCA3; the disease is prostate carcinoma.